# AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

> **NCT05198960** · PHASE3 · RECRUITING · sponsor: **University Hospital, Brest** · enrollment: 1308 (estimated)

## Conditions studied

- Polycythemia Vera
- Essential Thrombocythemia
- Prefibrotic/Early Primary Myelofibrosis
- JAK2 V617F
- High-risk Patients

## Interventions

- **DRUG:** Direct Oral Anticoagulants
- **DRUG:** Low-dose aspirin

## Key facts

- **NCT ID:** NCT05198960
- **Lead sponsor:** University Hospital, Brest
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-13
- **Primary completion:** 2027-07-13
- **Final completion:** 2027-07-13
- **Target enrollment:** 1308 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05198960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05198960, "AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05198960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*